Abstract
Marine organisms have been proven to be excellent sources of biologically active compounds against HIV. This review gives an overview of 132 natural products from marine sources obtained during the last decade (2002–2011), which exhibit anti-HIV activity toward different biological targets. Sponges contribute more than half of all anti-HIV natural products from marine organisms, mainly as alkaloids and cyclic depsipeptides. In addition, some macromolecules are considered as potential anti-HIV agents, including lectins from algae and marine invertebrates, as well as sulfated polysaccharides from algae. In the reviewed marine natural products, many active ingredients act as HIV entry inhibitors, one class of new anti-HIV agents, and may be regarded as potential candidates for the development of novel anti-HIV agents. The other features of development in the marine original anti-HIV natural products in this ten years are also discussed.
Keywords: Anti-HIV, HIV entry inhibitors, last decade, marine organisms, natural products, sponges, Marine Natural Products, biologically active compounds, 132 natural products, macromolecules
Current Medicinal Chemistry
Title:Marine Natural Products with Anti-HIV Activities in the Last Decade
Volume: 20 Issue: 7
Author(s): Xuefeng Zhou, Juan Liu, Bin Yang, Xiuping Lin, Xian-Wen Yang and Yonghong Liu
Affiliation:
Keywords: Anti-HIV, HIV entry inhibitors, last decade, marine organisms, natural products, sponges, Marine Natural Products, biologically active compounds, 132 natural products, macromolecules
Abstract: Marine organisms have been proven to be excellent sources of biologically active compounds against HIV. This review gives an overview of 132 natural products from marine sources obtained during the last decade (2002–2011), which exhibit anti-HIV activity toward different biological targets. Sponges contribute more than half of all anti-HIV natural products from marine organisms, mainly as alkaloids and cyclic depsipeptides. In addition, some macromolecules are considered as potential anti-HIV agents, including lectins from algae and marine invertebrates, as well as sulfated polysaccharides from algae. In the reviewed marine natural products, many active ingredients act as HIV entry inhibitors, one class of new anti-HIV agents, and may be regarded as potential candidates for the development of novel anti-HIV agents. The other features of development in the marine original anti-HIV natural products in this ten years are also discussed.
Export Options
About this article
Cite this article as:
Zhou Xuefeng, Liu Juan, Yang Bin, Lin Xiuping, Yang Xian-Wen and Liu Yonghong, Marine Natural Products with Anti-HIV Activities in the Last Decade, Current Medicinal Chemistry 2013; 20 (7) . https://dx.doi.org/10.2174/0929867311320070009
DOI https://dx.doi.org/10.2174/0929867311320070009 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Monoclonal Antibodies in the Treatment of Systemic Lupus Erythematosus
Current Drug Targets The Crosstalk of RAS with the TGF-β Family During Carcinoma Progression and its Implications for Targeted Cancer Therapy
Current Cancer Drug Targets Nitric Oxide: Cancer Target or Anticancer Agent?
Current Cancer Drug Targets Metabolomics: A Revolution for Novel Cancer Marker Identification
Combinatorial Chemistry & High Throughput Screening Novel and Emerging Drugs for Acute Myeloid Leukemia
Current Cancer Drug Targets Triptolide Induces Cell Apoptosis by Targeting H3K4me3 and Downstream Effector Proteins in KM3 Multiple Myeloma Cells
Current Pharmaceutical Biotechnology Molecularly Guided Therapy of Neuroblastoma: A Review of Different Approaches
Current Pharmaceutical Design Triterpene Derivatives as Inhibitors of Protein Involved in the Inflammatory Process: Molecules Interfering with Phospholipase A2, Cycloxygenase, and Lipoxygenase
Current Drug Targets The Targeted-liposome Delivery System of Antitumor Drugs
Current Drug Metabolism Quinoline-3-carboxylate Derivatives: A New Hope as an Antiproliferative Agent
Anti-Cancer Agents in Medicinal Chemistry Regulatory Circuitries Coordinated by Transcription Factors and microRNAs at the Cornerstone of Hematopoietic Stem Cell Self-Renewal and Differentiation
Current Stem Cell Research & Therapy Targeting Apoptosis Pathway with Natural Terpenoids: Implications for Treatment of Breast and Prostate Cancer
Current Drug Targets Progress Toward Vector Design for Hematopoietic Stem Cell Gene Therapy
Current Gene Therapy Production, Novel Assay Development and Clinical Applications of Monoclonal Antibodies
Recent Patents on Anti-Cancer Drug Discovery Nuclear Factor-κB: A Holy Grail in Cancer Prevention and Therapy
Current Signal Transduction Therapy MYC as Therapeutic Target for Embryonal Tumors: Potential and Challenges
Current Cancer Drug Targets Methionine Aminopeptidases as Potential Targets for Treatment of Gastrointestinal Cancers and other Tumors
Current Drug Targets Nanoparticle Drug Delivery Systems: Recent Patents and Applications in Nanomedicine
Recent Patents on Nanomedicine Gamma Secretase Inhibitor: Therapeutic Target via NOTCH Signaling in T Cell Acute Lymphoblastic Leukemia
Current Drug Targets Targeting DNA G-Quadruplex Structures with Peptide Nucleic Acids
Current Pharmaceutical Design